Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,283 INR | -0.51% | -2.54% | +15.25% |
03-29 | Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director | CI |
03-29 | Ipca Laboratories Limited Appoints Swati Arvind Patankar as an Independent Director | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 52.32 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.46 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.25% | 3.92B | C+ | ||
+31.79% | 588B | B | ||
-3.42% | 364B | C+ | ||
+18.02% | 326B | B- | ||
+4.27% | 285B | C+ | ||
+15.23% | 239B | B+ | ||
+9.94% | 210B | B- | ||
-7.20% | 200B | A+ | ||
+8.12% | 167B | C+ | ||
-1.42% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IPCALAB Stock
- Ratings Ipca Laboratories Limited